Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
CRM
IHD
Cosentyx® - Anti IL-17
Study
Indication
Phase
NCT03031782 (CAIN457F2304)
Psoriatic arthritis
Phase 3
Patients
80
Primary Outcome
Measures
Time to 33 flares
Arms Intervention
Secukinumab (pre-filled syringe) 75 mg
Placebo
Juvenile idiopathic arthritis subtypes of psoriatic and enthesitis-related arthritis
Target Patients
Read-out Milesstone(s)
H1-2021
Publication
H2-2021
73 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation